Why Pfizer’s Metsera Buyout Is a Lesson in FP&A Agility Pfizer Inc. is closing in on a $7.3 billion acquisition of Metsera, an anti-obesity drugmaker. If finalized, it would be one of the largest pharma M&A deals in years — and Pfizer’s boldest attempt to diversify as COVID-19 vaccine revenue falls. The prize? Entry into […]